Calviri, with a valuation of $165.8 million, is raising funds on StartEngine. It is a pre-market biotech company that has built a vaccine to prevent cancer in dogs. Calviri has done several pre-clinical studies to create vaccines that prevent cancer from starting in the first place and has completed a 5-year trial in over 800 dogs. The company discovered neoantigens that are absent from healthy cells and shared among tumors of different dogs, and is seeking USDA approval for an improved vaccine to be launched in 2025. Stephen Albert Johnson and Kathryn F. Sykes founded Calviri in December 2015. The current crowdfunding campaign has a minimum target of $9,998.10 and a maximum target of $1.23 million. The campaign proceeds will be used for research and development, company employment, and operations.